

October 3, 2017

CURRICULUM VITAE

NAME: Andrew Coop

TITLE: Professor
Associate Dean for Academic Affairs
Department of Pharmaceutical Sciences
University of Maryland School of Pharmacy
20 N. Pine Street, Rm N309E
Baltimore, Maryland 21201.
Phone 410-706-2029
Cell 443-801-6034
Fax 410-706-5017
Email acoop@rx.umaryland.edu
Webpage <http://www.pharmacy.umaryland.edu/faculty/acoop>

Chief Scientific Officer and co-Founder
ALT Pharmaceuticals, LLC
801 West Baltimore St.
Baltimore, Maryland, 21201
www.altpharmaceuticals.com

RESIDENCE STATUS: USA Permanent Resident

EDUCATION: B.A., M.A. St. Catherine's College,
University of Oxford,
Oxford, England, 1987-1991.
Thesis: *The Chemistry of Organolead Compounds.*
Supervisor: Dr. M. G. Moloney

Ph.D. School of Chemistry,
University of Bristol,
Bristol, England, 1991-1994.
Thesis: *Ring Constrained Analogues of Buprenorphine.*
Supervisor: Dr. J. W. Lewis.

PROFESSIONAL EXPERIENCE: 1994-1995 Postdoctoral Position:
School of Chemistry, University of Bristol,
Bristol, England.
Design of Delta Selective PET Ligands.

1995-1998 Fogarty Fellow:
Sponsor: Dr. K. C. Rice;
Laboratory of Medicinal Chemistry, NIDDK, NIH,
Bethesda, Maryland, USA.
Design and Synthesis of Delta Opioid Selective Ligands.

1999-2003 Assistant Professor:
Department of Pharmaceutical Sciences
University of Maryland School of Pharmacy
Baltimore, Maryland, USA.

2003-2008 Associate Professor:
Department of Pharmaceutical Sciences
University of Maryland School of Pharmacy
Baltimore, Maryland, USA.

ADMINISTRATIVE ROLES:	2008- Professor: Department of Pharmaceutical Sciences University of Maryland School of Pharmacy Baltimore, Maryland, USA.
	2006-2007 Vice Chair of Academic Affairs: Department of Pharmaceutical Sciences University of Maryland School of Pharmacy Baltimore, Maryland, USA.
	2007-2015 Chair: Department of Pharmaceutical Sciences University of Maryland School of Pharmacy Baltimore, Maryland, USA.
	2016- Associate Dean for Academic Affairs: University of Maryland School of Pharmacy Baltimore, Maryland, USA.

TEACHING EXPERIENCE:

UNIVERSITY OF MARYLAND:

Postdoctoral Fellows

Dr. Dean Meada
 Dr. Amina Kausar
 Dr. Weibin Chen
 Dr. Huifang Wu
 Dr. Rohit Kolhatkar
 Dr. Sucheta Kudrimoti
 Dr. Padmavani Bezawada
 Dr. William Motel
 Dr. Imran Ansari

Graduate students

Marco Bennett
 Linn Thatcher
 Matthew Metcalf
 Christopher Cunningham
 Susan Mercer
 Trudy Smith
 Marilyn Matthews
 Lidiya Stavitskaya
 Jessica Harker (MS)
 Chad Johnson

Technicians

Abby Foster
 Xiaowen Yang

Undergraduate and high school students

Nick Zink
 Elizabeth Kenez
 Christopher Berry
 Maura O'Neill
 Megan Pierson
 Deepti Patel
 Sami Karkar

Professional	2016-2017	PHAR 5019	Abilities Laboratory VI (Co-coursemanager 2016 -)
Professional	2014-2017	PHAR 5001	Applied Science and Therapeutics 1
Professional	2014-2016	PHAR 5002	Applied Science and Therapeutics 2
Professional	2014-2017	PHAR 5000	General Patient Management
Professional	2011-2015	PHAR 568	Applied Pharmaceutical Sciences (Coursemanager 2011 - 2015)
Professional	2003-2010	PHAR 533	Medicinal Chemistry I (Coursemaster 2003 - 2009)
Professional	2004-2016	PHAR 543	Medicinal Chemistry II (Coursemaster 2004 - 2010)
Professional	2005-2009	PHAR 531	Pharmaceutical Chemistry
Professional	2000-2006	PHAR 516	Principles of Pharmacy Education
Professional	2000-2007	PHEX 559A	Research Elective (Coursemaster 2006 - 2007)
Professional	2000-2017	PHMY 539	Special Projects (Coursemaster 2006 - 2007)
Professional	1999-2011	PHMY 551	Recent Advances in Pharmacology and Toxicology
Professional	2003-2006	PHMY 526	High Impact Presentations
Professional	2000-2003	PHAR 513	Drug Chemistry (Coursemaster 2000 - 2003)
Professional	2001-2003	PHAR 536	Pharmacology II
Professional	1999-2003	PHAR 544	Medicinal Chemistry (Coursemaster 2000 - 2003)
Professional	1999-2005	PHAR 581	Senior Colloquium (Co-coursemaster 2002 - 2003)
Graduate (PhD)	1999-2016	PHAR 600	Principles of Drug Design and Development (Module manager 2001 - 2016)
Graduate (PhD)	2000-2006	PHAR 751	Drug Design
Graduate (PhD)	1999-2007	PHAR 628	Bioanalytical and Pharmacological Methods (Co-coursemaster 1999)
Graduate (MS)	2014-2017	REGS 614	Drug and Biologics Discovery (Course manager 2015 - 2016) (Module manager 2014 -)

EDUCATIONAL WORKSHOPS at UMB

The New Pharmacy Resident and Faculty Guide to Teaching, University of Maryland School of Pharmacy, Baltimore, 8/16/05.

Topic: Difficult Subjects made Palatable.

The New Pharmacy Resident and Faculty Guide to Teaching, University of Maryland School of Pharmacy, Baltimore, 8/23/06.

Topic: Time Management: Balancing Teaching with Life

The New Pharmacy Resident and Faculty Guide to Teaching, University of Maryland School of Pharmacy, Baltimore, 7/23/07.

Topic: Time Management: Balancing Teaching with Life

UNIVERSITY OF MARYLAND SERVICE

UNIVERSITY OF MARYLAND BALTIMORE

Accreditation Coordinating Team (2017 -)

Advisory Committee for Expanding Resources for Faculty Teaching and Learning with Technology (2016 -)

UMB Academic Affairs Advisory Committee (2016 -)

Faculty Advisor: UMB Toastmasters (2014 -)

Campus Inquiry Committee (2013 - 2014)

“Responsible and Enduring Financial Model” Workgroup

University of Maryland Strategic Plan (2011)

UNIVERSITY OF MARYLAND GRADUATE SCHOOL, BALTIMORE

Chair: New Courses Committee, UMGSB Graduate Council (2006 - 07)

UMGSB Graduate Council (2005 - 2007)

New Courses Committee, UMGSB Graduate Council (2005 - 2006)

Chair: Graduate School Ad Hoc Grade Hearing Committee (2005)

SCHOOL OF PHARMACY

Associate Dean for Academic Affairs (2016 -)

Chair: Curriculum Committee (2016 -)

Co-Chair: Faculty Affairs Committee (2015 - 2016)

Administrative Board (2011 – 2015; 2016 -)

ACPE Self Study Steering Committee (2011 - 2012)

Executive Council (2007 – 2015; 2016 -)

Faculty Advisor: Phi Lambda Sigma (2013 -)

Pharmacy Hall Addition Research Subcommittee (2007 - 2009)

Pharmacy Hall Addition Steering Committee (2007 - 2010)

Shady Grove Steering Committee (2007 - 2010)

Assistant Dean Search Committee (2007)

Curriculum Committee (*Ex-officio*) (2006 - 2007)

Faculty Retreat Program Planning Committee (2006)

Student Affairs Committee (2005 - 2009)

Faculty Advisor: Class of 2009 (2005 - 2009)

Strategic Committee on Program Delivery (2005 - 2006)

Recruitment, Admissions, Tracking Committee (2005 - 2006)

Faculty Affairs Committee (2004 - 2006)

ACPE Self Study Task Force for Accreditation (2004 - 2006)

Chair: ACPE Self Study Sub-committee for Students (2004 - 2006)

Staff Appreciation Committee (2003)

Chair: Student Affairs Committee (2002 - 2004)

Executive Council (2002 - 2004)

Admissions Sub-committee (2000 - 2002)

Faculty Advisor: Phi Delta Chi (2000 - 2006)

DEPARTMENT OF PHARMACEUTICAL SCIENCES (PSC)

Department Strategic Planning Group (2015)

Department Chair (2007 - 2015)

PSC Executive Committee (2007 - 2015)

Chair: Chemistry/Biochemistry Faculty Search Committee (2007)

Vice-Chair of Academic Affairs (2006 - 2007)

Faculty Search Committee (Chemistry, X-Ray Crystallography,
Proteomics, Molecular Pharmacology) (2005 - 2006)

Steering Committee on "PSC Faculty Needs and the Future of PSC
Research" (2005)

Pharmacology Faculty Search Committee (2004 - 2005)

Chair: Chemistry Faculty Search Committee (2001 - 2004)

Chair: Drug Design Research Focus Group (2001 - 2002)

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER

Experimental Therapeutics Retreat Program Committee (2003)

AWARDS:

Fellow: American Association of Pharmaceutical Scientists (AAPS) **2016**

Fellow: College on Problems of Drug Dependence (CPDD) **2014**

James E. Wynn Memorial Award, American Association of Colleges of
Pharmacy (AACP), Chemistry Section, **2014**

Joseph Cochin Young Investigator Award, College on Problems of Drug
Dependence, **2003**.

Teacher of the Year, University of Maryland School of Pharmacy, **2001**.

Fogarty Fellowship (National Institutes of Health); April, **1995** -
December, **1998**.

Second and Third Year Organic Chemistry Practical Prize, **1990**, Dyson-
Perrins Laboratory, University of Oxford, Oxford, England.

SERVICE TO NATIONAL ORGANIZATIONS:

Chair-elect, Chair. Chemistry Section, AACP (2016 - 2018)

Chair: Awards Committee, CPDD (2017 -)

Chair: Programming Committee, Chemistry Section, AACP (2016 - 2017)

Awards Committee, CPDD (2015 - 2017)

Membership Strategic Oversight Committee, AAPS (2014 - 2016)

Industry, Academia, and Government Relations Committee, CPDD
(2014 - 2017)

Awards Committee, AACP Chemistry Section (2014 - 2015)

Rules and Regulations Committee, AACP (2013 - 2014)

Board of Directors, CPDD (2010 - 2014)

Credentials Committee, CPDD (2012 - 2015)

New Investigator Program/Award Grants Reviewer, AACP (2013-2015)

Member Survey Review Committee, Chemistry Section, AACP (2012-
2013)

Recruitment, Admissions, Pipeline Ad Hoc Committee, Graduate
Education Special Interest Group, AACP (2012-2013)

Publications Committee, AAPS (2008 - 2012)

Nominations Committee, CPDD (2011-2012; 2013-2014; 2015-2016;
2017-2018)

Secretary/Treasurer, DDD Section, AAPS (2007 - 2009)

Student and Post-Doc Outreach Committee, AAPS (2007)

Membership Committee, CPDD (2005 - 2008)

Electronic Communications Committee, CPDD (2002 - 2005)

Biological Coordinator. Drug Evaluation Committee, CPDD (2000 -
2007)

JOURNAL EDITORIAL BOARDS:

Drug and Alcohol Dependence (2017 -)

Drug Target Insights (2006 -)

Current Medicinal Chemistry - CNS Agents (2001 - 2003)

Mini-Reviews in Medicinal Chemistry (2001 - 2002)

CONFERENCES ORGANIZED:

“Drug Development Processes and Regulatory Approaches”.
University of Maryland, Baltimore, May 19-23, **2008**.

“Biology, Behavior, and Chemistry: Translation Research in Addiction”
Member, Organizing Committee, **2009 - 2010**.

SYMPOSIA CHAIRED:

Biology, Behavior, and Chemistry: Translation Research in Addiction, TX
March **2017**. The opioid epidemic: history, formulations,
regulations, and emergencies.

The College on Problems of Drug Dependence, San Juan, PR, June 19,
2014. Demystifying Medicinal Chemistry and Drug Design.

WORKSHOPS CHAIRED:

“Novel Techniques and Technologies in Chemistry and Pharmacology”.
College on Problems of Drug Dependence, San Juan, PR June
15, **2004**.

CONSULTING:

Expert witness, US Department of Justice
(US vs. Charles Burton Ritchie, Criminal No. 4:15-cr-18)
Office of Statewide Prosecution, Florida
Expert witness, US Department of Justice
(US vs. Thomas Vigliatura, Criminal No. 4:05cr40033-FDS)
Expert witness, US Department of Justice – did not go to trial.
(US vs. Michael J. Gilbert, Criminal No. 03-693 (JEI))
Expert witness, US Department of Justice
(US vs. David W. Linder, Criminal No. 4:02cr191)
Janssen Pharmaceutical Products
Darby and Darby Professional Corporation
Heenan Blaikie LLP
Actavis Mid Atlantic, LLC
Bingham McCutchen LLP

ADVISORY BOARDS:

Stevenson University Chemistry Advisory Board

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

College on Problems of Drug Dependence (CPDD)
American Chemical Society (ACS)
International Narcotics Research Conference (INRC)
American Association of Pharmaceutical Scientists (AAPS)
American Association of Colleges of Pharmacy (AACP)
Society of Physician Entrepreneurs (SOPE)
Rho-Chi Honor Society
Phi Lambda Sigma Pharmacy Leadership Society

MANUSCRIPT REVIEWER:

Journal of Medicinal Chemistry
Journal of Organic Chemistry
Journal of the American Chemical Society
Organic Letters
Journal of Pharmacology and Experimental Therapeutics
Drug and Alcohol Dependence
New England Journal of Medicine
Proceedings of the National Academy of Sciences, USA
Bioorganic and Medicinal Chemistry
Bioorganic and Medicinal Chemistry Letters
Tetrahedron
Tetrahedron Asymmetry
Tetrahedron Letters

SYNLETT
Drug Target Insights
Synapse
Pharmacology, Biochemistry, and Behavior
Pharmaceutical Research
Brain Research
Organic Process Research & Development
European Journal of Medicinal Chemistry
Organic and Biomolecular Chemistry
BMC - Bioinformatics
Chirality
Medicinal Chemistry Research
Current Medicinal Chemistry - CNS Agents
Mini-Reviews in Medicinal Chemistry
Brain, Behavior, and Immunity
Monatshefte fur Chemie - Chemical Monthly
Journal of Labeled Compounds and Radiopharmaceuticals

AD HOC STUDY SECTIONS:

National Institutes of Health RCMI Site Visit, College of Pharmacy,
Florida A&M University 10/6/02-10/8/02
National Institutes of Health RCMI Review Committee 11/7/02
National Cancer Institute, Special Emphasis Panel, ZCA1 SRRB-K J1
10/25/04-10/27/04
National Institute on Drug Abuse Medication Development Research
Review Subcommittee (NIDA-L) 6/6/05.
National Institute on Drug Abuse Medication Development Research
Review Subcommittee (NIDA-L) 10/5/05.
Canadian Institutes of Health Research. Drug Development Initiative –
Pilot Project Grants Committee. 1/12/06.
National Institute on Drug Abuse Medication Development Research
Review Subcommittee (NIDA-L) 3/7/06 and 3/21/06
National Institutes of Health, Special Emphasis Panel, ZRR1 BT-8 01
Interdisciplinary Research Consortium review – 8/12/06
National Institutes on Drug Abuse Rodent Locomotor and Discriminative
Stimulus Contract Review. 4/25/07.
National Cancer Institute, SBIR contract review. Development of
Anticancer Agents. 3/7/08.
National Institute of Mental Health “NIMH Chemical Synthesis and Drug
Supply Program” Contract Review. 6/25/08.
National Institutes of Health, SBIR Phase II, Design and Synthesis of
Treatment Agents N44DA-9-8874. 7/31/09
National Institutes of Health, National Cooperative Drug Discovery and
Development Groups (NCDDDG). ZMH1 ERB-C 03S, 3/1/10
National Institutes of Health, National Cooperative Drug Discovery and
Development Groups (NCDDDG). ZMH1 ERB-C 03S, 3/13/12
National Institutes of Health, National Cooperative Drug Discovery and
Development Groups (NCDDDG). ZMH1 ERB C 01 S, 11/15/12
National Institutes of Health. Therapeutics for Rare and Neglected
Diseases. NCATS 2/28/13-3/1/13
National Institutes of Health “NIMH Chemical Synthesis and Drug Supply
Program” Contract Review. 6/20/13
National Institutes of Health “Program Project: Pain and Drug Abuse
ZRG1 IFCN-B (40) P. 9/16/14
National Institutes of Health “Special Emphasis Panel” ZRG1 MDCN-
B(05). 7/21/15.
National Institutes of Health “Special Emphasis Panel” ZRG1 MDCN-
B(40) P. 11/17/15.
National Institutes of Health “Special Emphasis Panel” ZRG1 DKUS-P
(55) 2/19/16.

Chair: National Institutes of Health "Special Emphasis Panel" ZRG1
MDCN-B(05) 3/15/16
National Institutes of Health "Special Emphasis Panel" ZRG1 MDCN-B
(40) P. 9/8/16
National Institutes of Health "Special Emphasis Panel" ZNS1 SRB T (22)
BPN. 11/4/16

AD HOC GRANT REVIEWER:

National Science Foundation (NSF POWRE)
Austrian Science Fund (FWF)
National Institute on Drug Abuse (NIDA, CEBRA)
NIGMS Minority Biomedical Research Support - Support for Continuous
Research Excellence Program (MBRS-SCORE)
NIMH Psychoactive Drug Screening Program
U.S. Civilian Research and Development Foundation (CRDF)
NIDA SBIR Concept Review
ACCP New Investigator Program
Quebec-Flanders Bilateral Research Cooperation Program

BOOK REVIEWER:

Institute of Physics Publishing Ltd
John Wiley and Sons

RESEARCH FUNDING

1. Maryland Industrial Partnerships (MIPS). A Combination Test for the Detection of Illicit Drugs. 2/1/00-1/31/01. \$29,421 (Total Costs). Principle Investigator.
2. National Institute on Drug Abuse (NIDA, R01, DA 13583). Opioids with Delta Antagonist and Mu Agonist Activity. 2/1/01-1/31/13. Principle Investigator.
3. National Institute on Drug Abuse (NIDA, R01, DA 14986). GHB Abuse: Chemistry and Neurobiology. 9/26/01-7/31/04. \$199,870 (Total Costs). Co-Investigator - PI: Dr. Charles France, University of Texas Health Science Center at San Antonio.
4. National Institute on Drug Abuse (NIDA, R01, DA 13978). Development of Novel Agents with Anti-Cocaine Properties. 9/30/01-6/30/12. Co-Investigator - PI: Dr. Rae Matsumoto, University of Oklahoma, University of Mississippi, University of West Virginia).
5. Unihart, Inc. Synthesis of Analogs of Xenaldial. 11/1/04-10/31/05. \$29,200 (Total Costs). Principle Investigator.
6. Neuronascent, Inc. The Synthesis of Novel Neurogenic Agents. 7/1/05-2/28/06. \$8,000 (Total costs). Principle Investigator.
7. National Cancer Institute (NCI, R01 CA 107331). Restoration of Tumor Suppression Activity in Malignant Melanoma. 7/1/06-6/30/15. \$83,739 (Total costs). Co-Investigator - PI: Dr. David Weber, University of Maryland School of Medicine.
8. Samuel Waxman Foundation. Transcriptional Targeting in Translational Therapy. 7/1/06-6/30/09. Co-Investigator - PI: Dr. A. Melnick, Albert Einstein School of Medicine Yeshiva University.
9. Neuronascent, Inc. Further optimization of Neurogenic Agents. 4/1/07-12/31/07. \$11,500 (Total costs). Principle Investigator.
10. Maryland Department of Health and Mental Hygiene Opioid Analgesics for Cancer Pain with Reduced Tolerance.. 11/1/13-6/30/14. Principle Investigator.
11. University of Maryland Center of Excellence in Regulatory Science and Innovation (FDA, U01F004320). 09/15/11-09/14/14. Co-Investigator
12. Maryland Technology Development Corporation. UMB425: A unique opioid analgesic with reduced tolerance. 4/23/14-4/23/15. Principle Investigator.
13. National Institute of Mental Health (NIMH, R01, MH 107499). Preclinical identification of better antimuscarinic antidepressants. Co-Investigator – PI: Dr. James Woods, University of Michigan

CAREER ADVANCEMENT AWARDS

1. National Institute on Drug Abuse (K02, DA 019634). Reversing the Toxic Effects of Drugs of Abuse. 5/1/05-4/30/10. \$527,695 (Total Costs). Principle Investigator.

FELLOWSHIPS FOR GRADUATE STUDENTS AND POSTDOCTORAL RESEARCHERS

1. Linn N. Thatcher: National Research Service Award (NRSA). National Institute on Drug Abuse (NIDA F31, DA 15586). Opioids with a Reduced Potential to Produce Tolerance. 7/1/02-6/30/04. \$49,424 (Total Costs).
2. Matthew M. Metcalf: Slama Departmental Fellowship. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy. 9/1/04-4/30/05.

3. Matthew M. Metcalf: Ruth L. Kirschstein National Research Service Award (NRSA) (F31, DA 18025). National Institute on Drug Abuse (NIDA). Kappa Opioids Antagonists with a Shortened Duration of Action. 5/1/05-4/30/07. \$42,722 (Total costs).
4. Trudy Smith: University of Maryland Baltimore, Enrichment Fellowship. 8/1/05-7/31/07. \$38,000 (Total costs).
5. Christopher W. Cunningham: Ruth L. Kirschstein National Research Service Award (NRSA) (F31, DA 21049). National Institute on Drug Abuse (NIDA). Opioid Analgesics with Reduced Constipation. 8/1/06-9/30/08.
6. Susan L. Mercer: PSC Departmental Fellowship. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy. 9/1/07-6/30/08.
7. Trudy Smith: PSC Departmental Fellowship. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy. 9/1/08-6/30/09.

INVITED LECTURES

1. School of Chemistry, University of Bristol, Bristol, UK. August 7, **1996**.
(Topic: L-Selectride as a General O-Demethylating Agent for Opium Alkaloids and Derivatives).
2. Colgate University NIH Student Program, National Institutes of Health. October 19, **1998**.
(Topic: The Development and Application of Novel Methodology to Opioid Synthesis).
3. Laboratory of Medicinal Chemistry, National Institutes of Health, Bethesda. December 7, **2000**.
(Topic: The Development and Application of Novel Methodology to Opioid Synthesis).
4. The College on Problems of Drug Dependence, Quebec City, Quebec. June 11, **2002**. Symposium VII: "GHB: Chemical Biochemical, and Behavioral Effects". (Topic: The Chemistry of GHB Agonists and Antagonists).
5. University of Maryland Greenbaum Cancer Center, Baltimore, October 1, **2002**. (Topic: Drug Discovery and Development: From Protein Targets to Therapeutic Agents).
6. Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio. January 15, **2003** (Topic: The Symbiosis of Pharmacology and Chemistry in the Study of Biological Systems Involved in Drug Abuse).
7. National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD. February 26, **2003** (Topic: Chemical Approaches Towards Opioids with Reduced Potential for Tolerance).
8. Department of Chemistry and Biochemistry, Duquesne University, Pittsburgh, PA. April 4, **2003** (Topic: The Chemistry of Drugs of Abuse: Opioids and Gamma-Hydroxybutyrate).
9. Food and Drug Law Institute, Washington, DC, April 14, **2003**. Pharmaceutical Science: The Scientific Basis of Today's Drug Regulations (Topic: The Chemistry of Drug Design and Development).
10. University of Maryland Program in Oncology, Experimental Therapeutics Retreat, Baltimore, MD. May 22, **2003**. (Topic: Drug Lead Optimization).
11. The College on Problems of Drug Dependence, Bal Harbour, Florida. June 16, **2003**. Chemistry to Pharmacology - Pharmacology to Chemistry Workshop: (Topic: Opioids, Cocaine, and GHB: Examples of Synergism Between Pharmacologists and Chemists).
12. Department of Chemistry and Biochemistry, University of Maryland Baltimore County, Baltimore, MD. November 25, **2003** (Topic: The Chemistry of Drug Abuse: Opioids and Gamma-Hydroxybutyrate (GHB)).
13. The College on Problems of Drug Dependence, San Juan, PR. June 16, **2004**. Symposium XI: "Sigma Receptors: Evolution of an Enigma to a Therapeutic Target for Drugs of Abuse". (Topic: Sigma Receptors: From Promiscuous Ligands to Subtype Selective Agonists and Antagonists).
14. Pharmacists' Education and Assistance Committee Conference, Clarksville, MD. October 21, **2004**. "Crossing the Line": When Prescription Drug Use Becomes Abuse and Addiction. (Topic: Opioid Pharmacology).
15. American Chemical Society, Maryland Section, University of Maryland, Baltimore, MD. November 18, **2004**. (Topic: Synthetic Studies Towards Opioids Lacking Constipation as a Side-effect).
16. Division of Medicinal and Natural Products Chemistry, University of Iowa College of Pharmacy, Iowa City. March 8, **2005**. (Topic: Opioid Analgesia Without Constipation: Synthetic Approaches Towards Opioids with Novel Pharmacological Profiles).
17. University of Maryland Baltimore, Baltimore, MD. March 21, **2005**. Drug Development Processes and Regulatory Approaches Program. (Topic: Review of the Chemistry Section of the IND).

18. University of Maryland Baltimore, Baltimore, MD. May 22, **2006**. Drug Development Processes and Regulatory Approaches. II. (Topic: Review of the Chemistry Section of the IND).
19. College of Pharmacy University of Kentucky, Lexington, KY. September 8, **2006**. (Topic: Synthetic Studies Towards Opioids with a Mixed Pharmacological Profile).
20. College of Pharmacy University of Mississippi, University, MS. February 20, **2007**. (Topic: Adventures in Opioid Chemistry).
21. International Narcotics Research Conference, Berlin, Germany. July 10, **2007**. Symposium IV: "Medicinal Chemistry". (Topic: Kappa Opioid Antagonists).
22. Department of Chemistry, Brown University, Providence, RI. November 27, **2007**. (Topic: Synthetic Studies Towards Opioid Analgesics Lacking Tolerance).
23. School of Pharmacy, Howard University, Washington, DC. January 29, **2009**. (Topic: Towards Opioid Analgesics with Reduced Tolerance)
24. Biology, Behavior, and Chemistry, San Antonio, March 21-22, **2009**. (Topic: Therapeutics to Prevent Methamphetamine Neurotoxicity).
25. American Association of Pharmaceutical Sciences, Annual Meeting, Los Angeles, CA, November 11, **2009**. (Topic: Opioid, P-glycoprotein, and the Blood-Brain Barrier)
26. West Virginia University School of Pharmacy Research Day, Morgantown, WV. February 19, **2010**. (Keynote Speaker - Careers in Academia).
27. Department of Chemistry and Biochemistry, University of Maryland College Park. September 9, **2010**.
28. Lipscomb College of Pharmacy, Nashville, TN. October 19, **2010**. (Topic: The Symbiosis of Pharmacology and Chemistry in the Study of Biological Systems Involved in Drug Abuse)
29. Department of Chemistry, Franklin & Marshall College, PA. February 1, **2011**. (Topic: Chemistry and Biology - Partners in the Study of Drug Abuse)
30. Universities at Shady Grove, Rockville, MD. Fourth Annual Biomedical Sciences Day, November 15, **2012**. (Topic: New and Evolving Therapeutics – A Collaborative Approach)
31. Biology, Behavior, and Chemistry, San Antonio, March 9-10, **2013**. (Topic: Medicinal chemistry of mu opioid agonists).
32. The College on Problems of Drug Dependence, San Diego, CA. June 16, **2013**. "Late-Breaking Research". (Topic: UMB425: A dual profile mu agonist/delta antagonist opioid with reduced antinociceptive tolerance).
33. Johns Hopkins Alliance for Science and Technology Development, Baltimore, MD February 18, 2014. (Topic: UMB425: An Opioid Analgesic with less Tolerance than Morphine).
34. The College on Problems of Drug Dependence, San Juan, PR, June 15, **2014**. President's Lecture. (Topic: The Harrison Act at 100. Past, present and future science behind the search for new opioid Analgesics)
35. The College on Problems of Drug Dependence, San Juan, PR, June 18, **2014**. Drug Evaluation History Forum. The Drug Evaluation program of the CPDD: History and Scope. Role: Discussant.
36. The College on Problems of Drug Dependence, San Juan, PR, June 19, **2014**. Demystifying Medicinal Chemistry and Drug Design Symposium (Topic: Fundamental Principles of Drug Design).

37. University of Maryland School of Pharmacy, Computer-Aided Drug Design Symposium, Baltimore, MD, June 24, **2014**. (Topic: Next Generation Opioid Analgesics).
38. Biology, Behavior, and Chemistry, San Antonio, March 14-15, **2015**. After Dinner Lecture. Role: After Dinner Speaker on Alternate Careers for Graduate Students.
39. Concordia University School of Pharmacy, Mequon, WI, April 15, **2015**. (Topic: UMB425: A Unique Opioid Analgesic with Lower Tolerance).
40. International Narcotics Research Conference, Phoenix, AZ. June 16, **2015**. Advances in Therapeutic Design (Topic: UMB425: A Unique Opioid Analgesic with Lower Tolerance).
41. Department of Chemistry, University of Notre Dame of Maryland, Baltimore, MD October 15, **2015**. (Topic: Reduction of prescription opioid abuse through new opioid analgesics lacking tolerance and dependence).
42. The College on Problems of Drug Dependence, Palm Springs, CA, June 13, **2016**. Town Hall Industry/Academia Forum. New Challenges and Opportunities from the Collaborative Environment (Topic: Start-ups from an Academic View).
43. MdAIR, Baltimore, MD, November 11, **2016** (Topic: A Collaborative Process to Measure Faculty Workload)
44. University of Maryland Center to Advance Chronic Pain Research, Baltimore, MD. November 17, **2016**. Chronic Pain Management and Opioid Abuse: We Need a "Fix". (Topic: Solving prescription opioid abuse: New drugs or new formulations?)
45. Biology, Behavior, and Chemistry, San Antonio, TX. March, 4-5, **2017**. (Topic: Beyond formulations: Solving the opioid epidemic with new chemical entities)
46. AACP Webinar, June 8, **2017** (Topic: A Collaborative Process to Measure Faculty Workload)
47. The College on Problems of Drug Dependence, Montreal, Canada, June 20, **2017**. Town Hall Industry/Academia Forum. Industry, government, and academia as a collaborative environment for development of a product for the treatment of substance use disorders. Role: Discussant.
48. The College on Problems of Drug Dependence, Montreal, Canada, June 22, **2017**. La Chimie: Drug Development Strategies. (Topic: UMB 426: A pyranomorphinan with a profile of mu agonism/delta antagonism)

BIBLIOGRAPHY

1. J. W. Barton, A. Coop and J. W. Lewis: Diels-Alder Reactions of Thebaines with Cycloalkenones; LiBF₄ as a Novel Diels-Alder Catalyst. *Tetrahedron Lett.*, **1993**, 34, 6777-6778.
2. J. E. H. Buston, A. Coop, R. Keady, M. G. Moloney and R. M. Thompson: The Synthesis, Characterization and Reactivity of some Lead (IV) Carboxylates. *J. Chem. Res.(m)*, **1994**, 1101-1116. (*J. Chem. Res.(s)*, **1994**, 205)
3. A. Coop, K. Grivas, S. Husbands, J. W. Lewis and J. Porter: Ring Constrained Analogues of the Thevinones; Diels-Alder Reactions of Thebaines with 1-Indenone and Methylene Cycloalkenones. *Tetrahedron Lett.*, **1995**, 36, 1689-1692.
4. A. Coop, K. Grivas, S. Husbands and J. W. Lewis: Methylation of the Enolates of Thevinone and Some Analogues. *Tetrahedron*, **1995**, 51, 9681-9698.
5. L. Guo, A. Coop, J. W. Lewis and J. R. Traynor: Affinity and Efficacy Studies of Ring Constrained Analogues of Buprenorphine at mu-Opioid Receptors. *Analgesia*, **1995**, 1, 450-452.
6. A. Coop, J. W. Lewis and K. C. Rice: Direct and Simple Conversion of Thebaine to Oripavine. *J. Org. Chem.*, **1996**, 61, 6774.
7. A. Coop, J. W. Janetka, J. W. Lewis and K. C. Rice: L-Selectride as a General Reagent for the O-Demethylation and N-Decarbomethoxylation of Opium Alkaloids and Derivatives. *J. Org. Chem.*, **1998**, 63, 4392-4396.
8. A. Coop and K. C. Rice: L-Selectride as Convenient Reagent for the Selective Cleavage of Carbamates. *Tetrahedron Lett.*, **1998**, 39, 8933-8934.
9. E. L. May, A. E. Jacobson, M. V. Mattson, A. Coop, M. D. Aceto, E. R. Bowman, J. R. Traynor, J. H. Woods and L. S. Harris: Synthesis, *In Vitro*, and *In Vivo* Activity of *N-p*-Substituted-Benzyl(-)- and (+)-*N*-Normetazocines, (-)- and (+)-*N*-Nor-morphinans, *N*-Nor-Ketobemidones, and (-)-*N*-Nor-4,5-epoxymorphinans. *Med. Chem. Res.*, **1998**, 8, 311-321.
10. A. Coop and K. C. Rice: A Novel Synthesis of Thebaine from Codeine. *Heterocycles*, **1998**, 49, 43-47.
11. A. Coop and K. C. Rice: Direct and Simple Conversion of Codeine to Thebainone-A and Dihydro-thebainone. *Heterocycles*, **1999**, 50, 39-42.
12. A. Coop and A. E. Jacobson: The LMC Delta Opioid Recognition Pharmacophore. Comparison of SNC80 and Oxymorbindole. *Bioorg. Med. Chem. Lett.*, **1999**, 9, 357-362.
13. A. Coop, R. B. Rothman, C. Dersch, J. Partilla, F. Porreca, P. Davis, A. E. Jacobson and K. C. Rice: Delta Opioid Affinity and Selectivity of 4-Hydroxy-3-methoxyindolomorphinan Analogues Related to Naltrindole. *J. Med. Chem.*, **1999**, 42, 1673-1679.
14. A. Coop and K. C. Rice: Studies into the Direct Oxidation of Codeinone to 14-Hydroxycodeinone. *Tetrahedron*, **1999**, 55, 11429-11436.
15. H. Yu, L. Wang, X. Tian, J. Flippen-Anderson, A. Coop and K. C. Rice: Synthesis of a Novel 7,14 β -Ethano-Bridged Opiate. *Heterocycles*, **1999**, 51, 2343-2347.
16. J. R. Traynor, L. Guo, A. Coop, J. W. Lewis and J. H. Woods: Ring-Constrained Orvinols as Analogues of Buprenorphine: Differences in Opioid Activity Related to the Conformation of the C-20 Hydroxyl Group. *J. Pharmacol Exp. Ther.*, **1999**, 291, 1093-1099.
17. S. W. Breeden, A. Coop, S. M. Husbands, and J. W. Lewis: 6-O-Demethylation of the Thevinols with Lithium Aluminium Hydride: Selective Demethylation of a Tertiary Alkyl Methyl Ether in the Presence of an Aryl Methyl Ether. *Helv. Chim. Acta*, **1999**, 82, 1978-1980.

18. X. Zhang, K. C. Rice, S. N. Calderon, H. Kayakiri, L. Smith, A. Coop, A. E. Jacobson, R. B. Rothman, P. Davis, K. Becketts and F. Porreca: Probes for Narcotic Receptor Mediated Phenomena. 26. Synthesis and Biological Evaluation of Diarylmethyl Piperazines and Diarylmethyl Piperidines as Novel, Nonpeptidic Delta Opioid Receptor Ligands. *J. Med. Chem.*, **1999**, *42*, 5455-5463.
19. A. Coop, J. Pinto, L. Wang, R. B. Rothman, C. Dersch, A. E. Jacobson and K. C. Rice: Delta Opioid Binding Selectivity of 3-Ether Analogs of Naltrindole. *Bioorg. Med. Chem. Lett.*, **1999**, *9*, 3435-3438.
20. D. Y. Maeda, W. Williams, W. D. Bowen and A. Coop: A Sigma-1 Receptor Selective Analog of BD1008. A Potential Substitute for (+)-Opioids in Sigma Receptor Binding Assays. *Bioorg. Med. Chem. Lett.*, **2000**, *10*, 17-18.
21. A. Coop, I. Berzetei-Gurske, J. Burnside, L. Toll, J. R. Traynor, S. M. Husbands, and J. W. Lewis: Structural Determinants of Opioid Activity in the Orvinols and Related Structures: Ethers of 7,8-Cyclopentano-Fused Analogs of Buprenorphine. *Helv. Chim. Acta*, **2000**, *83*, 687-693.
22. A. Coop, C. L. Norton, I. Berzetei-Gurske, J. Burnside, L. Toll, S. M. Husbands, and J. W. Lewis: Structural Determinants of Opioid Activity in the Orvinols and Related Structures: Ethers of Orvinol and Isoorvinol. *J. Med. Chem.*, **2000**, *43*, 1852-1857.
23. M. S. Furness, X. Zhang, A. Coop, A. E. Jacobson, R. B. Rothman, C. M. Dersch, Q.-X. Zheng, H. Xu, and K. C. Rice: Probes for Narcotic Receptor Mediated Phenomena. 27. Synthesis and Pharmacological Evaluation of Selective Delta-Opioid Receptor Agonists from 4-[(αR)- α -(2*S*,5*R*)-4-Substituted-2,5-dimethyl-1-piperazinyl]-3-methoxybenzyl]-*N,N*-diethylbenzamides and their Enantiomers. *J. Med. Chem.*, **2000**, *43*, 3193-3196.
24. D. C. Broom, L. Guo, A. Coop, S. M. Husbands, J. W. Lewis, J. H. Woods, and J. R. Traynor: BU48: A Novel Buprenorphine Analog that Exhibits Delta-Opioid-Mediated Convulsions but not Delta-Opioid-Mediated Antinociception in Mice. *J. Pharmacol. Exp. Ther.*, **2000**, *294*, 1195-1200.
25. D. Y. Maeda and A. Coop: Studies into the Direct Conversion of the Indolomorphinans into their 4-Phenolic Derivatives. *Tetrahedron*, **2000**, *56*, 7399-7402.
26. I. Derrick, A. Coop, S. M. Al-Mousawi, S. M. Husbands, and J. W. Lewis: Perchloric Acid Induced Epimerisation of the Thevinones: An Improved Synthesis of 7 β -Dihydrothevinones. *Tetrahedron Lett.*, **2000**, *41*, 7571-7576.
27. A. Coop, A. E. Jacobson, M. D. Aceto, L. S. Harris, J. R. Traynor, J. H. Woods, and K. C. Rice: *N*-Cyclohexylethyl-*N*-noroxymorphindole: A Mu-Opioid Preferring Analog of Naltrindole. *Bioorg. Med. Chem. Lett.*, **2000**, *10*, 2449-2451.
28. S. McLamore, T. Ullrich, R. B. Rothman, H. Xu, C. M. Dersch, R. Horel, A. Coop, P. Davis, F. Porreca, A. E. Jacobson, and K. C. Rice: The Effect of *N*-Alkyl and *N*-Alkenyl Substituents in Noroxymorphindole, 17-Substituted-6,7-dehydro-4,5 α -epoxy-3,14-dihydroxy-6,7:2'3'-indolomorphinans, on Opioid Receptor Affinity, Selectivity and Efficacy. *J. Med. Chem.*, **2001**, *44*, 1471-1474.
29. D. Y. Meada and A. Coop: An Improved Hydrolysis of 7 α -Chloro-7 β -cyano-6,14-endo-ethenotetrahydrothebaine to its 7-Oxo Derivative. *Heterocycles*, **2001**, *55*, 1147-1149.
30. S. M. Huang, T. Bisogno, T. J. Petros, S. Y. Chang, P. A. Zavitsanos, R. E. Zipkin, R. Sivakumar, A. Coop, D. Y. Maeda, L. Petrocellis, S. Burstein, V. DiMarzo, J. M. Walker: Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member that Inhibits Pain. *J. Biol. Chem.*, **2001**, *276*, 42639-42644.
31. A. K. Mehta, N. M. Muschaweck, D. Y. Maeda, A. Coop, and M. K. Ticku: Binding Characteristics of the γ -Hydroxybutyric acid (GHB) Receptor Antagonist [3 H]NCS-382 in the Rat Brain. *J. Pharmacol. Exp. Ther.*, **2001**, *299*, 1148-1153.

32. L.-W. Hsin, X. Tian, E. L. Webster, A. Coop, T. M. Caldwell, A. E. Jacobson, G. P. Chrousos, P. W. Gold, K. E. Habib, A. Ayala, W. C. Eckelman, C. Contoreggi, K. C. Rice: CRHR₁ Receptor Binding and Lipophilicity of Pyrrolopyrimidines, Potential Nonpeptide Corticotropin-Releasing Hormone Type 1 Receptor Antagonists. *Bioorg. Med. Chem.*, **2002**, *10*, 175-183.
33. D. Y. Maeda, W. Williams, W. E. Kim, L. N. Thatcher, W. D. Bowen, and A. Coop: *N*-Arylalkylpiperidines as High Affinity Sigma-1 and Sigma-2 Receptor Ligands: Phenylpropylamines as Potential Leads for Sigma-2 Agents. *Bioorg. Med. Chem. Lett.*, **2002**, *12*, 497-500.
34. Cook, C. D.; Aceto, M. D.; Coop, A.; Beardsley, P. M. Effects of the Putative Antagonist NCS382 on the Behavioral Pharmacological Actions of Gamma-Hydroxybutyrate in Mice. *Psychopharmacology*, **2002**, *160*, 99-106.
35. K. Crawford, A. Coop, and W. D. Bowen: Sigma-2 Receptors Regulate Changes in Sphingolipid Levels in Breast Tumor Cells. *Eur. J. Pharmacol.*, **2002**, *443*, 207-209.
36. E. L. May, A. Coop, J. H. Woods, M. D. Aceto, E. R. Bowman, L. S. Harris, J. R. Traynor: *N*-(Trifluoromethyl)benzyl Substituted *N*-Normetazocines and *N*-Norketobemidones. *Bioorg. Med. Chem.*, **2003**, *11*, 31-31.
37. W. Chen, M. D. Metcalf, A. Coop, J. L. Flippen-Anderson, J. R. Deschamps: 5-Butylthevinone: Stereochemistry of the Diels-Alder Reaction of 5-Butylthebaine with 3-Buten-2-one. *Acta Cryst. E*, **2003**, *E59*, o114-o116.
38. W. Chen, H. Wu, D. Bernard, M. D. Metcalf, J. R. Deschamps, J. L. Flippen-Anderson, A. D. MacKerell, and A. Coop: Rearrangement of 5-Trimethylsilylthebaine on Treatment with L-Selectride: An Efficient Synthesis of (+)-Bractazonine. *J. Org. Chem.*, **2003**, *68*, 1929-1932.
39. D. Bernard, A. Coop, and A. D. MacKerell: 2D Conformationally Sampled Pharmacophore: A Ligand Based Pharmacophore to Differentiate Delta Opioid Agonists from Antagonists. *J. Am. Chem. Soc.*, **2003**, *125*, 3101-3107.
40. A. Foster, H. Wu, W. Chen, W. Williams, W. D. Bowen, R. R. Matsumoto, and A. Coop: 1,4-Dibenzylpiperazines Possess Anticocaine Activity. *Bioorg. Med. Chem. Lett.*, **2003**, *13*, 749-751.
41. L. R. McMahon, A. Coop, C. P. France, G. Winger, W. L. Woolverton: Evaluation of the Reinforcing and Discriminative Stimulus Effects of 1,4-Butanediol and Gamma-butyrolactone in Rhesus Monkeys. *Eur. J. Pharmacol.* **2003**, *466*, 113-120.
42. E. Greiner, M. Spetea, R. Krassnig, F. Schullner, M. D. Aceto, L. S. Harris, J. R. Traynor, J. H. Woods, A. Coop, H. Schmidhammer: Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 18. *N*-Substituted 14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties: Extending the Scope of Common Structure-Activity Relationships: *J. Med. Chem.* **2003**, *46*, 1758-1763.
43. R. M. van Well, H. O. Overkleef, J. H. van Boom, A. Coop, J. B. Wang, H. Wang, G. A. van der Marel, M. Overhand: Synthesis of Novel Sugar Amino Acids via a Curtius Rearrangement. *Eur. J. Org. Chem.* **2003**, 1704-1710.
44. L. P. Carter, L. Flores, H. Wu, W. Chen, A.W. Unzeitiz, A. Coop, C.P. France: The Role of GABA_B Receptors in the Discriminative Stimulus Effects of γ -Hydroxybutyrate in Rats: Time Course and Antagonism Studies. *J. Pharmacol. Exp. Ther.* **2003**, *305*, 668-674.
45. H. Wu, N. Zink, L. P. Carter, A. K. Mehta, R. J. Hernandez, M. Ticku, R. Lamb, C. France, and A. Coop: A Tertiary Alcohol Analog of Gamma-Hydroxybutyric Acid as a Specific Gamma-Hydroxybutyric Acid Receptor Ligand. *J. Pharmacol. Exp. Ther.* **2003**, *305*, 675-679.
46. J. W. Janetka, M. S. Furness, X. Zhang, A. Coop, J. E. Folk, M. V. Mattson, A. E. Jacobson, K. C. Rice: Enantioconvergent Synthesis of (-)-(2*R*,5*S*)-1-Allyl-2,5-dimethylpiperazine, an Intermediate to δ -Opioid Ligands. *J. Org. Chem.* **2003**, *68*, 3976-3980.

47. R. J. Lamb, J. Munn, N. Duiker, A. Coop, H. Wu, W. Koek, C. P. France: Interactions of γ -Hydroxy Butyrate with Ethanol and NCS-382. *Eur. J. Pharmacol.* **2003**, *470*, 157-162.
48. J. Schutz, M. Spetea, M. Koch, M. D. Aceto, L. S. Harris, A. Coop, H. Schmidhammer: Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 20. 14-Phenylpropoxymetopon: An Extremely Powerful Analgesic: *J. Med. Chem.* **2003**, *46*, 4182-4187.
49. S. Tolle-Sander, K. A. Lentz, D. Y. Maeda, A. Coop, J. E. Polli: Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate. *Mol. Pharmaceut.* **2004**, *1*, 40-48.
50. L. P. Carter, L. Flores, H. Wu, W. Chen, C. M. Cruz, R. J. Lamb, W. Koek, A. Coop, C.P. France: Effects of GHB on Schedule-Controlled Responding in Rats: Role of GHB and GABA_B Receptors. *J. Pharmacol. Exp. Ther.* **2004**, *308*, 182-188.
51. J. R. Deschamps, A. Coop, D. A. Parrish, K. C. Rice: 7 β ,14 β -Epoxyhydrocodone-6,6-dimethoxy ketal: An Unusual Oxetane Containing Opioid. *Acta Cryst. E* **2004**, *E60*, o331-o333.
52. W. Koek, L. R. Flores, L. P. Carter, R. J. Lamb, W. Chen, H. Wu, A. Coop, C. P. France: Discriminative Stimulus Effects of γ -Hydroxybutyric Acid in Pigeons: Role of Diazepam-sensitive and -Insensitive GABA_A and GABA_B Receptors. *J. Pharmacol. Exp. Ther.* **2004**, *308*, 904-911.
53. A. T. Macias, R. J. Hernandez, A. K. Metha, A. D. MacKerell, M. K. Ticku, A. Coop: 3-Chloropropanoic Acid (UMB66): A Ligand for the Gamma-Hydroxybutyric Acid Receptor Lacking a 4-Hydroxyl Group. *Bioorg. Med. Chem.* **2004**, *12*, 1643-1647.
54. D. Parrish, W. Chen, A. Coop, J. R. Deschamps: 7 β -Chloro-6,14-endo-etheno-6,7,8,14-tetrahydrothebaine. *Acta Cryst. E* **2004**, *E60*, o793-o794.
55. L. P. Carter, A. W. Unzeitig, H. Wu, W. Chen, A. Coop, W. Koek, C. P. France: The Discriminative Stimulus effects of *gamma*-Hydroxybutyrate and Related Compounds in Rats Discriminating Baclofen or Diazepam: The Role of GABA_B and GABA_A Receptors. *J. Pharmacol. Exp. Ther.* **2004**, *309*, 540-547.
56. R. R. Matsumoto, D. L. Gilmore, B. Pouw, W. D. Bowen, W. Williams, A. Kausar, A. Coop: Novel Analogs of the Sigma Receptor Ligand BD1008 Attenuate Cocaine-Induced Toxicity in Mice. *Eur. J. Pharmacol.* **2004**, *492*, 21-29.
57. M. Spetea, F. Schullner, R. C. Moisa, I. P. Berzetei-Gurske, B. Schraml, C. Dorfner, M. D. Aceto, L. S. Harris, A. Coop, H. Schmidhammer: Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 21. Novel 4-Alkoxy and 14-Phenylpropyl Derivatives of the mu Opioid receptor Antagonist Cyprodime: *J. Med. Chem.* **2004**, *47*, 3242-3247.
58. W. Chen, G. D. Strahan, D. A. Parrish, J. R. Deschamps, A. Coop: Studies into the Diels-Alder Reactions of 5-Trimethylsilylthebaine. *Tetrahedron Lett.* **2005**, *46*, 131-133.
59. W. E. Fantegrossi, G. Winger, J. H. Woods, W. L. Woolverton, A. Coop: Reinforcing and Discriminative Stimulus Effects of 1-Benzylpiperazine and Trifluoromethylphenylpiperazine in Rhesus Monkeys. *Drug Alcohol Depend.* **2005**, *77*, 161-168.
60. W. Chen, D. A. Parrish, J. R. Deschamps, A. Coop: Functionalization of the 6,14-Bridge of the Orvinols. 1. Preparation and Diels-Alder Reaction of 7-Phenylsilylthebaines. *Helv. Chim. Acta* **2005**, *88*, 822-829.
61. H. Wu, D. Bernard, W. Chen, G. D. Strahan, J. R. Deschamps, D. A. Parrish, J. W. Lewis, A. D. MacKerell, A. Coop: Functionalization of the 6,14-Bridge of the Orvinols. 2. Preparation of 18- and 19-Hydroxyl Substituted Thevinols and their Treatment with Benzyl Bromide. *J. Org. Chem.* **2005**, *70*, 1907-1910.

62. L. P. Carter, W. Chen, H. Wu, A. K. Mehta, R. J. Hernandez, M. K. Ticku, A. Coop, W. Koek, C. P. France: Comparison of the Behavioral Effects of Gamma-Hydroxybutyric Acid (GHB) and its 4-Methyl-Substituted Analog, Gamma-Hydroxyvaleric Acid (GHV). *Drug Alcohol Depend.* **2005**, *78*, 91-99.
63. L. P. Carter, H. Wu, W. Chen, M. M. Matthews, A. K. Mehta, R. J. Hernandez, J. A. Thomson, M. K. Ticku, A. Coop, W. Koek, C. P. France: Novel Gamma-Hydroxybutyric Acid (GHB) Analogs Share Some, But Not All, of the Behavioral Effects of GHB and GABA_B Receptor Agonists. *J. Pharmacol. Exp. Ther.* **2005**, *313*, 1314-1323.
64. W. Koek, L. P. Carter, R. J. Lamb, W. Chen, H. Wu, A. Coop, C. P. France: Discriminative Stimulus Effects of γ -Hydroxybutyrate (GHB) in Rats Discriminating GHB from Baclofen and Diazepam. *J. Pharmacol. Exp. Ther.* **2005**, *314*, 170-179.
65. W. Chen, H. Wu, R. J. Hernandez, A. K. Mehta, M. K. Ticku, C. P. France, A. Coop: Ethers of 3-Hydroxyphenylacetic Acid as Selective Gamma-Hydroxybutyric Acid Receptor Ligands. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3201-3202.
66. H. Wu, L. N. Thatcher, D. Bernard, D. A. Parrish, J. R. Deschamps, K. C. Rice, A. D. MacKerell, A. Coop: The Position of Coordination of the Lithium Ion Determines the Regioselectivity of Demethylations of 3,4-Dimethoxymorphinans with L-Selectride. *Org. Lett.* **2005**, *7*, 2531-2534.
67. D. A. Parrish, L. N. Thatcher, H. Wu, A. Coop, J. R. Deschamps: 7-[*E*]-Benzylidene-14-hydroxy-3,4-dimethoxy-17-methylmorphinan-6-one. *Acta Cryst. E.* **2005**, *E61*, o2617-o2618.
68. M. Spetea, E. Greiner, M. D. Aceto, L. S. Harris, A. Coop, H. Schmidhammer: Effect of a 6-Cyano Substituent in 14-Oxygenated *N*-Methylmorphinans on Opioid Receptor Binding and Antinociceptive Potency. *J. Med. Chem.* **2005**, *48*, 5052-5055.
69. W. E. Fantegrossi, A. W. Harrington, J. R. Eckler, R. A. Rabin, J. C. Winter, A. Coop, K. C. Rice, J. W. Woods: Hallucinogen-like actions of 2,5-dimethoxy-4-(*n*)-propylthiophenethylamine (2C-T-7) in mice and rats. *Psychopharmacology* **2005**, *181*, 496-503.
70. D. Bernard, A. Coop, A. D. MacKerell: Conformationally Sampled Pharmacophore (CSP) for Peptidic Delta Opioid Ligands. *J. Med. Chem.* **2005**, *48*, 7773-7780.
71. C. D. Cook, L. Biddlestone, A. Coop, P. M. Beardsley: Effects of Combining Ethanol with Gamma-Hydroxybutyrate (GHB) on the Discriminative Stimulus, Locomotor and the Motor-Impairing Actions of GHB in Mice. *Psychopharmacology* **2006**, *185*, 112-122.
72. W. Koek, W. Chen, S. L. Mercer, A. Coop, C. P. France: Discriminative Stimulus Effects of γ -Hydroxybutyrate: Role of training Dose. *J. Pharmacol. Exp. Ther.* **2006**, *317*, 409-417.
73. W. E. Fantegrossi, A. W. Harrington, C. L. Kiessel, J. R. Eckler, R. A. Rabin, J. C. Winter, A. Coop, K. C. Rice, J. H. Woods: Hallucinogen-like Actions of 5-Methoxy-*N,N*-diisopropyltryptamine in Mice and Rats. *Pharmacol. Biochem. Behav.* **2006**, *83*, 122-129.
74. W. Koek, L.P. Carter, H. Wu, A. Coop, C.P. France: Discriminative Stimulus Effects of Flumazenil: Perceptual Masking by Baclofen, and Lack of Substitution with Gamma-Hydroxybutyrate and its Precursors 1,4-Butanediol and Gamma-Butyrolactone.. *Behav. Pharmacol.* **2006**, *17*, 239-247.
75. C. W. Cunningham, L. N. Thatcher, A. Coop: The Methylation of Non-acidic Alcohols of Alkaloids with TMS-Diazomethane: Conversion of Codeine to Codeine-6-methyl Ether. *Heterocycles.* **2006**, *68*, 837-840.
76. L. P. Carter, W. Chen, A. Coop, W. Koek, C. P. France: Discriminative Stimulus Effects of GHB and GABA_B Agonists are Differentially Attenuated by CGP35348 in rats. *Eur. J. Pharmacol.* **2006**, *538*, 85-93

77. A. Balakrishnan, S. A. Wring, A. Coop, J. E. Polli: Influence of Charge and Steric Bulk in C-24 Region on the Interaction of Bile Acids with Human Apical Sodium Dependent Bile Acid transporter (hASBT). *Mol.Pharmaceut.* **2006**, *3*, 282-292.
78. A. Daniels, E. Ayala, B. Pouw, W. Chen, A. Coop, R. R. Matsumoto. *N*-[2-(*m*-Methoxyphenyl)ethyl]-*N*-ethyl-2-(1-pyrrolidinyl)ethylamine (UMB 116) is a Novel Antagonist for Cocaine-Induced Effects. *Eur. J. Pharmacol.* **2006**, *542*, 61-68.
79. S. L. Mercer, H. E. Hassan, C. W. Cunningham, N. D. Eddington, A. Coop: Opioids and Efflux Transporters. 1. P-Glycoprotein Substrate Activity of *N*-Substituted Analogs of Merperidine. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1160-1162.
80. R. R. Matsumoto, B. Pouw, A. L. Mack, A. Daniels, A. Coop: Effects of UMB24 and (±)-SM21, putative Sigma-2-preferring Antagonists, on Behavioral, Toxic, and Stimulant Effects of Cocaine in Mice. *Pharmacol. Biochem. Behav.* **2007**, *86*, 86-91.
81. K. Cheng, I. J. Kim, M.-J. Lee, S. A. Adah, T. J. Raymond, E. Bilsky, M. D. Aceto, E. L. May, L. S. Harris, A. Coop, C. M. Dersch, R. B. Rothman, A. E. Jacobson, K. C. Rice: Opioid Ligands with Mixed Properties from Substituted Enantiomeric *N*-Phenethyl-5-phenylmorphans. Synthesis of a μ -Agonist delta-Antagonist and delta-Inverse Agonists. *Org. Biomol. Chem.* **2007**, *5*, 1177-1190.
82. D. Bernard, A. Coop, A. D. MacKerell: Quantitative Conformationally Sampled Pharmacophore (CSP) for Delta Opioid Ligands: Reevaluation of Hydrophobic Moieties Essential for Biological Activity. *J. Med. Chem.* **2007**, *50*, 1799-1809.
83. W. Koek, S. L. Mercer, A. Coop: Cataleptic Effects of GHB, its precursor GBL, and GABA-B Agonists: Differential Antagonism by CGP35348. *Psychopharmacology* **2007**, *192*, 407-414.
84. A. C. Hiebel, Y. S. Lee, E. Bilsky, D. Giuvelis, J. R. Deschamps, M. D. Aceto, E. L. May, L. S. Harris, A. Coop, C. M. Dersch, R. B. Rothman, A. E. Jacobson, K. C. Rice: Probes for Narcotic receptor Mediated Phenomena. 34. Synthesis and Structure-Activity Relationships of a Potent μ -Agonist δ -Antagonist and an Exceedingly Potent Antinociceptive in the Enantiomeric 9-Substituted 5-(3-Hydroxyphenyl)-*N*-phenylethylmorphans Series. *J. Med. Chem.* **2007**, *50*, 3765-3776
85. H. Wu, T. A. Smith, H. Huang, J. B. Wang, D. A. Parrish, J. R. Deschamps, A. Coop: Functionalization of the 6,14-Bridge of the Orvinols. Part 3. Preparation and Evaluation of 18- and 19-Hydroxyl Substituted Orvinols. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 4829-4831.
86. H. E. Hassan, A. L. Myers, I. J. Lee, A. Coop, N. Eddington: Oxycodone Induces Overexpression of P-glycoprotein (ABCB1) and Affects Paclitaxel's Tissue Distribution in Sprague Dawley rats. *J. Pharmt. Sci.* **2007**, *96*, 2494- 2506.
87. T. A. Smith, L. N. Thatcher, A. Coop: 3-Hydroxy-4-methoxyindolomorphinans as Delta Opioid Selective Ligands. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5175-5176.
88. J. Wang, A. L. Mack, A. Coop, R. R. Matsumoto: Novel Sigma Receptor Agonists Produce Antidepressant-like Effects in Mice. *Eur. Neuropsychopharmacol.* **2007**, *17*, 708-716.
89. H. L. Yarosh, E. B. Katz, A. Coop, W. E. Fantegrossi: MDMA-like Behavioral Effects of *N*-Substituted piperazines in the Mouse. *Pharmacol. Biochem. Behav.* **2007**, *88*, 18-27.
90. M. D. Metcalf, A. Coop: 5'-Halogenated Analogs of Oxymorphindole. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5916-5917.
91. M. D. Metcalf, M. D. Aceto, L. S. Harris, J. H. Woods, J. R. Traynor, A. Coop, E. L. May: The Influence of Esters and Carboxylic Acids as the *N*-substituent of Opioids. 1. Benzomorphans. *Bioorg. Med. Chem.* **2008**, *16*, 869-873.

92. C. W. Cunningham, S. L. Mercer, H. E. Hassan, J. R. Traynor, N. D. Eddington, A. Coop: Opioids and Efflux Transporters. Part 2: P-Glycoprotein Substrate Activity of 3- and 6-Substituted Morphine Analogs. *J. Med. Chem.* **2008**, *51*, 2316-2320.
93. S. L. Mercer, R. R. Matsumoto, A. Coop: 4-Cyano-4-phenylpiperidines as Highly Selective Sigma-1 Selective Ligands. *Eur. J. Med. Chem.* **2008**, *43*, 1304-1308.
94. S. L. Mercer, C. W. Cunningham, N. D. Eddington, A. Coop: Opioids and Efflux Transporters. Part 3: P-Glycoprotein Substrate Activity of 3-Hydroxyl Addition to Meperidine Analogs. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3638-3640.
95. T. Smith, X. Yang, H. Wu, B. Pouw, R. R. Matsumoto, A. Coop: Trifluoromethoxyl Substituted Phenylethylene Diamines as High Affinity Sigma Receptor Ligands with Potent Anti-cocaine Actions. *J. Med. Chem.* **2008**, *51*, 3322-3325.
96. R. R. Matsumoto, J. Shaikh, L. L. Wilson, S. Vedam, A. Coop: AC927, A Selective Sigma Receptor Antagonist, Attenuates the Locomotor Stimulant and Neurotoxic Effects of Methamphetamine in Mice. *Eur. Neuropsychopharmacol.* **2008**, *18*, 871-881.
97. S. R. Burks, J. Ni, S. Muralidharan, A. Coop, J. P.Y. Kao, G. M. Rosen: Optimization of Labile Esters for Esterase-Assisted Accumulation of Nitroxides into Cells: A Model for In Vivo EPR Imaging. *Bioconjugate Chem.* **2008**, *19*, 2068-2071.
98. T. H. Charpentier, P. T. Wilder, M. A. Liriano, K. M. Varney, E. Pozharski, A. D. MacKerell, A. Coop, E. A. Toth, D. J. Weber: Divalent Metal Ion Complexes of S100B in the Absence and Presence of Pentamidine. *J. Mol. Bio.* **2008**, *382*, 56-73.
99. H. E. Hassan, S.L. Mercer, C.W. Cunningham, A. Coop, N.D. Eddington: Evaluation of the P-Glycoprotein (Abcb1) Affinity Status of a Series of Morphine Analogs: Comparative Study with Meperidine Analogs to Identify Opioids with Minimal P-Glycoprotein Interactions. *Int. J. Pharm.* **2009**, *375*, 48-54.
100. T.H. Charpentier, P.T. Wilder, M.A. Liriano, K.M. Varney, S. Zhong, A. Coop, E. Pozharski, A.D. MacKerell Jr, E.A. Toth, D. J.Weber: Small molecules bound to unique sites in the target protein binding cleft of calcium-bound S100B as characterized by nuclear magnetic resonance and X-ray crystallography. *Biochemistry.* **2009**, *48*, 6202-6212.
101. W. Koek, S. L. Mercer, A. Coop, and C. P. France: Behavioral Effects of GHB, its Precursor GBL, and GABA_B Receptor Agonists: Time Course, and Differential Antagonism by the GABA_B Receptor Antagonist CGP35348. *J. Pharmacol. Exp. Ther.* **2009**, *330*, 876-883.
102. H. E. Hassan, A.L. Myers, A. Coop, N. D. Eddington: Differential Involvement of P-Glycoprotein (ABCB1) in Permeability, Tissue Distribution, and Antinociceptive Activity of Methadone, Buprenorphine, and Diprenorphine: In Vitro and In Vivo Evaluation. *J. Pharm. Sci.* **2009**, *98*, 4928-4940.
103. H. E. Hassan, A. L. Myers, I. J. Lee, H. Chen, A. Coop, N. D. Eddington: Regulation of Gene Expression in Brain Tissues of Rats Repeatedly Treated by the Highly Abused Opioid Agonist, Oxycodone: Microarray Profiling and Gene Mapping Analysis. *Drug Metab. Dispos.* **2010**, *38*, 157-167.
104. L. C. Cerchietti, A. F. Ghetu, X. Zhu, G. F. Da Silva, S. Zhong, M. Matthews, K. L. Bunting, J. M. Polo, C. Farès, C. H. Arrowsmith, S. N. Yang, M. Garcia, A. Coop, A. D. Mackerell, Jr., G. G. Privé, A. Melnick.: A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo. *Cancer Cell*, **2010**, *17*, 315-316.
105. P. T. Wilder, T. H. Charpentier, M. A. Liriano, K. Gianni, K. M. Varney, E. Pozharski, A. Coop, E. A. Toth, A. D. MacKerell, D. J. Weber: In Vitro Screening and Structural Characterization of Inhibitors of the S100B-p53 Interaction. *Int. J. High Throughput Screening* **2010**, *1*, 109-126.
106. R. R. Matsumoto, S-M. Li, J. L. Katz, W. E. Fantegross, A. Coop: Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine. *Drug Alcohol Depend.* **2011**, *118*, 40-47.

107. J. Shim, A. Coop, A. D. MacKerell: Consensus 3D Model of μ -Opioid Receptor Ligand Efficacy Based on a Quantitative Conformationally Sampled Pharmacophore. *J. Phys. Chem. B.* **2011**, *115*, 7487–7496.
108. M. J. Seminerio, N. Kaushal, J. Shaikh, J. D. Huber, A. Coop, R. R. Matsumoto: Sigma (σ) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice. *Pharmacol. Biochem. and Behav.* **2011**, *98*, 12–20.
109. N. Kaushal, M. Elliott, M. J. Robson, A. K. V. Iyer, Y. Rojanasakul, A. Coop, R. R. Matsumoto: AC927, a sigma ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. *Mol Pharmacol.* **2012**, *81*, 299-308.
110. L. Stavitskaya, J. Shim, J. R. Healy, R. R. Matsumoto, A. D. MacKerell Jr., A. Coop. Deconstructing 14-phenylpropyloxymetopon: Minimal requirements for binding to mu opioid receptors. *Bioorg. Med. Chem.* **2012**, *20*, 4556-4563.
111. L. E. McKnight, E. P. Raman, P. Bezawada, S. Kudrimoti, P. T. Wilder, K. G. Hartman, R. Godoy-Ruiz, E. A. Toth, A. Coop, A. D. MacKerell, Jr., D. J. Weber. Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B. *ACS Med. Chem. Lett.*, **2012**, *3*, 975–979.
112. M. J. Robson, M. J. Seminerio, C. R. McCurdy, A. Coop, R. R. Matsumoto. σ Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. *Pharmacol. Reports.* **2013**, *65*, 343-349.
113. J. R. Healy, P. Bezawada, J. Shim, J. W. Jones, M. A. Kane, A. D. MacKerell, Jr, A. Coop, R. R. Matsumoto. Synthesis, Modeling, and Pharmacological Evaluation of UMB 425, a Mixed μ Agonist/ δ Antagonist Opioid Analgesic with Reduced Tolerance Liabilities. *ACS Chemical Neuroscience* **2013**, *4*, 1256-1266.
114. J. Shim, A. Coop, and A. D. MacKerell, Jr. Molecular details of the activation of the μ opioid receptor. *J. Chem. Phys. B.* **2013**, *117*, 7907-7917.
115. L. Stavitskaya, M. J. Seminerio, J. R. Healy, B. Noorbakhsh, R. R. Matsumoto, A. Coop. Effect of ring-constrained phenylpropyloxyethylamines on sigma receptors. *Bioorg. Med. Chem.* **2013**, *21*, 4923-4927.
116. W. C. Motel, E. Viard, B. Pouw, K. Martin, R. R. Matsumoto, A. Coop. Chlorophenylpiperazine analogues as high affinity dopamine transporter ligands. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 6920-6922.
117. C. W. Cunningham, J. R. Deschamps, A. Coop. A one-step synthesis of β -bromocodide from codeine. *J. Pharm. Sci. Pharmacol.* **2014**, *1*, 54-56.
118. M. D. Metcalf, A. D. Rosicky, H. E. Hassan, N. D. Eddington, A. Coop, C. W. Cunningham, S. L. Mercer. Opioids and efflux transporters. Part 4: Influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues. *Bioorg. Med. Chem. Lett.*, **2014**, *24*, 3592-3595.
119. T. B. Haddou, D. Malfacini, G. Calo, M. D. Aceto, L. S. Harris, J. R. Traynor, A. Coop, H. Schmidhammer, M. Spetea. Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor. *Molecular Pain* **2014**, *10*, 48.
120. M. C. Cavalier, M. I. Ansari, A. D. Pierce, P. T. Wilder, L. E. McKnight, E. Raman, D. B. Neau, P. Bezawada, M. J. Alasady, T. H. Charpentier, K. M. Varney, E. A. Toth, A. D. MacKerell, Jr., A. Coop, and D. J. Weber. Small Molecule Inhibitors of Ca²⁺-S100B Reveal Two Protein Conformations. *J. Med. Chem.*, **2016**, *59*, 592-608.

PATENTS

1. A. Coop and K. C. Rice: Novel Methods of O-Demethylation and N-Deprotection. US 6,395,900 (May 28, 2002) (6,291,675).

2. J. E. Polli, K. A. Lentz, D. Y. Maeda and A. Coop: Bile Acid Containing Prodrugs with Enhanced Bioavailability. Australian Letters Patent Number 2001253226 (September 21, 2006).
3. A. Coop, M. K. Ticku, C. P. France: Ethers of 3-Hydroxyphenylacetic Acid as Selective Gamma-Hydroxybutyric Acid Receptor Ligands and Therapeutic Uses Thereof. US 7,838,556 (November 23, 2010)

PATENT APPLICATIONS

1. A. Coop and K. C. Rice: Direct C-14 Oxidation of Opioids. Application Serial No. WO 00/66588.
2. A. Coop, A. D. MacKerell, R. R. Matsumoto: Opioid Analgesics with Reduced Tolerance. Submitted 12/18/12. PCT application: PCT/US2014/021155.
3. A. Coop, A. D. MacKerell: Pyranomorphinan Opioid Analgesics With Reduced Tolerance Due to Mixed Profile of Mu Agonism and Delta Antagonism and Methods of Using the Same. Submitted 3/4/16. U.S. Provisional Application Number: 62/303,496

INVENTION DISCLOSURES

INVITED REVIEWS

1. A. Coop and K. C. Rice: Role of Delta Opioid Receptors in Biological Processes. *Drug News and Perspectives*, **2000**, 13 (8). 481-487.
2. A. Coop and A. D. MacKerell: The Future of Opioid Analgesics. *Am. J. Pharm. Educ.*, **2002**, 66, 153-156.
3. S. N. Calderon and A. Coop: SNC 80 and Related Delta Opioid Agonists. *Curr. Pharmaceut. Des.* **2004**, 10, 733-742.
4. D. Bernard, A. Coop, A. D. MacKerell: Computer-Aided Drug Design: Structure-Activity Relationships of Delta Opioid Ligands. *Med. Chem. Rev. Online* **2005**, 2, 277-291.
5. M. D. Metcalf, A. Coop: Kappa Opioid Antagonists: Past Successes and Future Prospects. *AAPS J.* **2005**, 7, E704-E722.
6. C. W. Cunningham, A. Coop: Therapeutic Applications of Opioid Antagonists. *Chimica Oggi - Chemistry Today*. **2006**, 24 (3), 54-57.
7. M. M. Matthews, D. J. Weber, P. S. Shapiro, A. Coop, A. D. MacKerell, Jr.: Inhibition of Protein-Protein Interactions with Low Molecular Weight Compounds. *Current Trends in Medicinal Chemistry* **2008**, 5, 21-32.
8. A. Chayan, A. Coop, J. E. Polli, A. D. MacKerell, Jr.: Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally Sampled Pharmacophore Approach. *Curr. Computer-Aided Drug Des.* **2011**, 7, 10-22.
9. L. Stavitskaya, A. Coop: Most Recent Developments and Modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan Derivatives. *Mini Rev. Med. Chem.*, **2011**, 11, 1002-1008.
10. S. L. Mercer, A. Coop: Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance. *Curr. Topics Med. Chem.*, **2011**, 11, 1157-1164.
11. W. C. Motel, A. Coop, and C. W. Cunningham. Cholinergic Modulation by Opioid Receptor Ligands: Potential Application to Alzheimer's Disease. *Mini Reviews in Medicinal Chemistry*, **2013**, 13, 456-466.

12. A. Coop, A. D. MacKerell, S. Fletcher: Polypharmacology in Drug Design. *AAPS Newsmagazine (July Issue)* **2015**, *18*, 14-18.

MONOGRAPHS

1. A. Coop and A. E. Jacobson: Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXIV. Drug Evaluation Committee of the College on Problems of Drug Dependence (2000). *National Institute on Drug Abuse Research Monograph Series*, **2001**, *181*, 109-122.
2. A. Coop: Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXV. Drug Evaluation Committee of the College on Problems of Drug Dependence (2001). *National Institute on Drug Abuse Research Monograph Series*, **2002**, *182*, 124-138.
3. A. Coop: Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXVI. Drug Evaluation Committee of the College on Problems of Drug Dependence (2002). *National Institute on Drug Abuse Research Monograph Series*, **2003**, *183*, 152-169.
4. A. Coop: Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXVII. Drug Evaluation Committee of the College on Problems of Drug Dependence (2003). *National Institute on Drug Abuse Research Monograph Series*, **2004**, *184*, 135-151.
5. A. Coop: Biological Evaluation of Opioids, Stimulants, and Depressants. I. An Overview of the Studies Performed by the Drug Evaluation Committee of the College on Problems of Drug Dependence (2004). *National Institute on Drug Abuse Research Monograph Series*, **2005**, *185*, 105-130.
6. A. Coop: Biological Evaluation of Opioids, Stimulants, and Depressants. II. An Overview of the Studies Performed by the Drug Evaluation Committee of the College on Problems of Drug Dependence (2005). *National Institute on Drug Abuse Research Monograph Series*, **2006**, *186*, 145-162.
7. A. Coop: An Overview of the Studies Performed by the Drug Evaluation Committee of the College on Problems of Drug Dependence (2006). *National Institute on Drug Abuse Research Monograph Series*, **2007**, *187*, 100-112.

BOOK CHAPTERS

1. A. H. Newman and A. Coop: *Medicinal Chemistry: New Chemical Classes and Subtype-Selective Ligands*. in "*Sigma Receptors: Chemistry, Cell Biology, and Clinical Implications*", R. R. Matsumoto, W. D. Bowen, T. P. Su, (Eds.), Springer-Verlag, **2007** (ISBN-10: 0-387-36512-5).
2. Hartman, K.G., Wilder, W.T., Varney, K., MacKerell, A.D., Jr., Coop, A., Njar, V., Zimmer, D., Lapidus, R., and Weber, D.J, "Inhibiting S100B in Malignant Melanoma," in "Melanoma – From Early Detection to Treatment, G. Huynh and T. Duc, editors, INTECH Open Science, Chapter 24, **2013**, DOI: 10.5772/55176

POSTERS AND PRESENTATIONS AT AACP

1. L. Lebovitz, A. Coop, M. R. de Bittner, I. H. Zuckerman: *Applied Pharmaceutical Sciences: An Innovative, Interdisciplinary Approach to Educating Both Students and Faculty*. **2013**
<http://www.ajpe.org/doi/full/10.5688/ajpe775109>
2. L. Lebovitz, N. D. Eddington, M. R. de Bittner, A. Coop, W. J. Cooper, C. D. Mullins: *One Hundred Eighty Thousand Minutes or Two Thousand Hours; How Do You Measure a Year*. **2014**
<http://www.ajpe.org/doi/full/10.5688/ajpe785111>

3. J. E. Polli, P. Shapiro, A. Coop: *Design and Implementation of an Online MS in Regulatory Science Degree Program for Working Professionals*. **2015** <http://www.ajpe.org/doi/full/10.5688/ajpe795S4>
4. A. Coop, M. R. de Bittner: *Dueling Professors: Integrated Education and Faculty Development through "Double Acts."* **2015** <http://www.ajpe.org/doi/full/10.5688/ajpe795S4>
5. L. Lebovitz, R. N. Dalby, C. Layson-Wolf, A. Coop, S. R. Tucker, J. Mattingly, N. J. Brandt: *Pharmacy Curriculum Outcomes Assessment (PCOA). Love it or Hate it, It's Required!* **2015** <http://www.ajpe.org/doi/full/10.5688/ajpe795S4>
6. A. Coop, L. Lebovitz, S. R. Tucker, G. Anagnostou, C. Klimas, R.N. Dalby: *Creating a Comprehensive Exam to Prepare Students for the PCOA*. **2016** <http://www.ajpe.org/doi/full/10.5688/ajpe805S2>
7. G. Anagnostou, L. Finn, S. R. Tucker, A. Coop: *Developing a Data Driven Approach to Exam Administration and Support Using ExamSoft*. **2017** <http://www.ajpe.org/doi/full/10.5688/ajpe815S5>
8. A. Coop, P. Shapiro, J. E. Polli: *America's Got Regulatory Science Talent" Competition Inspires Future Innovators*. **2017** <http://www.ajpe.org/doi/full/10.5688/ajpe815S5>
9. A. Coop, S. R. Tucker, R. J. Ceraul: *Communication Breakdown, It's Always the Same! An Academic Chemist and the Mainstream Media*. **2017** <http://www.ajpe.org/doi/full/10.5688/ajpe815S5>
10. M. I. Ansari, S. R. Tucker, A. Coop: *Filling the Pipeline of Science Faculty Through Situated Learning*. **2017** <http://www.ajpe.org/doi/full/10.5688/ajpe815S5>
11. S. R. Tucker, J. E. Polli, A. Coop, M. J. Bondy, M. Rietschel: *Ensuring Quality in Online Graduate Education Using the Quality Matters Rubric*. **2017** <http://www.ajpe.org/doi/full/10.5688/ajpe815S5>
12. A. Coop. Participation and presentation at satellite Grant Writing Workshop. **2017**.